Results 11 to 20 of about 4,434,840 (211)
ASTCT Clinical practice recommendations for transplant and cellular therapies in diffuse large B-cell lymphoma
, 2023 Autologous hematopoietic cell transplantation (auto-HCT) has long remained the standard approach for patients with relapsed/refractory (R/R) chemosensitive diffuse large B-cell lymphoma (DLBCL).Reid, Erin, Perales, Miguel-Angel, Rezvani, Andrew R, Lee, Catherine J, Mei, Matthew, Kumar, Ambuj, Awan, Farrukh T, Holter-Chakrabarty, Jennifer, Gopal, Ajay K, Sauter, Craig S, Epperla, Narendranath, Oluwole, Olalekan, Trotman, Judith, Kharfan-Dabaja, Mohamed A, Carpenter, Paul A, Lekakis, Lazaros, Nathan, Sunita, Abutalib, Syed A, Kekre, Natasha, Chen, Yi-Bin, Phillips, Adrienne A, Zurko, Joanna, Nastoupil, Loretta, Hamadani, Mehdi, Lin, Yi, Locke, Frederick L +25 morecore +3 more sourcesAmerican Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma [PDF]
, 2021 Autologous (auto-) and allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities in contemporary treatment algorithms for mantle cell lymphoma (MCL).Robinson, Stephen P.,, Cohen, Jonathon B.,, Kahl, Brad, Shadman, Mazyar, Savani, Bipin N., Phillips, Tycel,, Savani, Bipin, Shadman, Mazyar,, Kharfan-Dabaja, Mohamed A., Kamdar, Manali,, Locke, Frederick L.,, Carlo-Stella, Carmello,, Ghosh, Nilanjan, Inwards, David J.,, Inwards, David J., Cohen, Jonathon B., Phillips, Tycel, Maddocks, Kami J.,, Dreger, Peter,, Carlo-Stella, Carmello, Bachanova, Veronika, Friedberg, Jonathan W., Bachanova, Veronika,, Kenkre, Vaishalee P., Friedberg, Jonathan W.,, Aljurf, Mahmoud,, Sureda, Anna,, Kumar, Ambuj,, Dreyling, Martin,, Hill, Brian T.,, Lund University., Ahmed, Sairah, Leonard, John P., Lunning, Matthew,, Kenkre, Vaishalee P.,, Dreyling, Martin, Kamdar, Manali, Kharfan-Dabaja, Mohamed A.,, Leonard, John P.,, Carlo-Stella, Carmelo, Jerkeman, Mats, Aljurf, Mahmoud, Smith, Sonali M.,, Sauter, Craig S., Maddocks, Kami J., Jerkeman, Mats,, Herrera, Alex F.,, Munshi, Pashna N., Wang, Michael,, Robinson, Stephen P., Ahmed, Sairah,, Kumar, Ambuj, Lunning, Matthew, Sureda, Anna, Smith, Sonali M., Dreger, Peter, Fenske, Timothy S.,, Hamadani, Mehdi, Munshi, Pashna N.,, Cashen, Amanda F., Savani, Bipin,, Locke, Frederick L., Hill, Brian T., Kahl, Brad,, Sauter, Craig S.,, Wang, Michael, Fenske, Timothy S., Herrera, Alex F., Hamadani, Mehdi,, Ghosh, Nilanjan,, Cashen, Amanda F.,, Cashen, Amanda F, Munshi, Pashna N, et al.,, Jonathon B. Cohen, Frederick L. Locke, Sairah Ahmed, Amanda F. Cashen, Bipin Savani, Pashna N. Munshi, Brian T. Hill, Craig S. Sauter, Jonathan W. Friedberg, Alex F. Herrera, Kami J. Maddocks, David J. Inwards, Nilanjan Ghosh, Michael Wang, Tycel Phillips, Ambuj Kumar, Vaishalee P. Kenkre, Mazyar Shadman, Stephen P. Robinson, Veronika Bachanova, Carmello Carlo-Stella, Mats Jerkeman, Mohamed A. Kharfan-Dabaja, Matthew Lunning, Manali Kamdar, Peter Dreger, Sonali M. Smith, Anna Sureda, John P. Leonard, Timothy S. Fenske, Brad Kahl, Mehdi Hamadani, Martin Dreyling, Mahmoud Aljurf +107 morecore +1 more sourceImproved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis
Haematologica, 2021
High-dose chemotherapy and autologous stem-cell transplant (HDC/ASCT) is standard treatment for chemosensitive relapsed classical Hodgkin lymphoma, although outcomes of high-risk relapse (HRR) patients remain suboptimal.Yago Nieto, Stephen Gruschkus, Benigno C. Valdez, Roy B. Jones, Paolo Anderlini, Chitra Hosing, Uday Popat, Muzaffar Qazilbash, Partow Kebriaei, Amin Alousi, Neeraj Saini, Samer Srour, Katayoun Rezvani, Jeremy Ramdial, Melissa Barnett, Alison Gulbis, Terri Lynn Shigle, Sairah Ahmed, Swaminathan Iyer, Hun Lee, Ranjit Nair, Simrit Parmar, Raphael Steiner, Bouthaina Dabaja, Chelsea Pinnix, Jillian Gunther, Branko Cuglievan, Kris Mahadeo, Sajad Khazal, Hubert Chuang, Richard Champlin, Elizabeth J. Shpall, Borje S. Andersson +32 moredoaj +1 more sourceIn Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
Turkish Journal of Hematology, 2023 Objective: Hemophilia A is an X-linked recessive bleeding disorder caused by a deficiency of plasma coagulation factor VIII (FVIII), and it accounts for about 80%-85% of all cases of hemophilia.Cansu Hemşinlioğlu, Elif Sibel Aslan, Cihan Tastan, Didem Çakırsoy, Raife Dilek Turan, Utku Seyis, Muhammer Elek, Gözde Sır Karakuş, Ömür Selin Günaydın, Selen Abanuz, Derya Dilek Kançağı, Bulut Yurtsever, Koray Yalçın, Murat Kasap, Ercüment Ovalı +14 moredoaj +1 more sourceProceedings from the BMT CTN Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma. [PDF]
, 2022 The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup conducted a workshop on Immune and Cellular Therapy in Multiple Myeloma on January 7, 2022.John, Lukas, Usmani, Saad Z, Raluca Verona, Leslie A. Crews, Holstein, Sarah A, Giles, Hannah, Saad Z. Usmani, Holstein, Sarah A., Bhutani, Manisha, Verona, Raluca, Azab, Abdel Kareem, Pasquini, Marcelo C., Sarah A. Holstein, Monica Shokeen, Kylee Maclachlan, Flavia Pichiorri, Shy, Brian R., Hillengass, Jens, Fotis Asimakopoulos, Crews, Leslie A, Hannah Giles, McCarthy, Philip L., Maclachlan, Kylee, McCarthy, Philip L, Lukas John, Brian R. Shy, Manisha Bhutani, Marcelo C. Pasquini, Cupedo, Tom, Usmani, Saad Z., Crews, Leslie A., Shokeen, Monica, Eric L. Smith, Lydia Lee, Giada Bianchi, Shari Kaiser, Philip L. McCarthy, Sarah Gooding, Jens Hillengass, Bianchi, Giada, Gooding, Sarah, Kaiser, Shari, Smith, Eric L, Asimakopoulos, Fotis, Pichiorri, Flavia, Tom Cupedo, Pasquini, Marcelo C, Shah, Nina, Abdel Kareem Azab, Lee, Lydia, Shy, Brian R, Nina Shah, Smith, Eric L. +52 morecore +1 more sourceNovel Cellular Therapies for Hepatocellular Carcinoma [PDF]
, 2022 Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death worldwide. Most patients present with advanced disease, and current gold-standard management using tyrosine kinase inhibitors or immune checkpoint inhibitors (ICIs ...Roddie, C, Claire Roddie, Harriet Roddy, Tim Meyer, Roddy, H, Meyer, T +5 morecore +1 more sourcePreclinical Evaluation of the Tumorigenic and Immunomodulatory Properties of Human Bone Marrow Mesenchymal Stromal Cell Populations with Clonal Trisomy 5
Stem Cells International, 2022 Cytogenetic aberrations may emerge in human mesenchymal stromal cells (MSC) during ex vivo expansion for cell therapy. We have detected clonal trisomy 5 in two distinct autologous MSC products expanded from bone marrow which, based on the current quality Maria Susana Joya Marodin, Juliana A. Godoy, Raquel M. Alves-Paiva, Kelen Alvarez, Thiago Giove Mitsugi, Ana Cristina Victorino Krepischi, Nelson Hamerschlak, Maria Augusta Tezelli Bortolini, Rodrigo Castro, Andrea T. Kondo, Jose Mauro Kutner, Oswaldo Keith Okamoto +11 moredoaj +1 more source